Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

- PMLiVE

Amgen gets priority review for chronic heart failure hope

Raises expectations for early entry onto US market for ivabradine

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

- PMLiVE

Amgen hit as Kyprolis fails myeloma study

Inability to improve overall survival could dent expanded use prospects

Novartis building

Novartis will file heart failure drug before year-end

New data reinforces view that LCZ696 can reduce cardiovascular deaths

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

Novartis building

Novartis: novel antimalarial is ‘game-changing’

Says cipargamin could be first new class of malaria drugs in 20 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links